Sysmex Inostics

Sysmex Inostics

Biotechnologieforschung

Baltimore, Maryland 3.892 Follower:innen

Together for a Better Healthcare Journey

Info

Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). Plasma-Safe-SeQs NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.

Branche
Biotechnologieforschung
Größe
51–200 Beschäftigte
Hauptsitz
Baltimore, Maryland
Art
Kapitalgesellschaft (AG, GmbH, UG etc.)
Gegründet
2008
Spezialgebiete
Mutation Detection, Sequence Analysis, Oncology, Molecular Diagnostics, circulating tumor dna, ctDNA, Plasma NGS, Next Generation Sequencing , digital PCR , BEAMing, Clinical Trials , NGS, CLIA, GCP, Cancer, Molecular Testing, Medicine, Research, IVD Kit , Plasma-Safe-SeqS, Liquid Biopsy, cfDNA, cell free DNA, cfHPV-DNA und LBx

Orte

Beschäftigte von Sysmex Inostics

Updates

Ähnliche Seiten

Jobs durchsuchen